http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#Head http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#assertion http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#provenance http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#pubinfo http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#assertion http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://identifiers.org/MONDO:0001945 http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/CHEBI:2619 http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association http://www.w3.org/2000/01/rdf-schema#label Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#cohort http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association https://w3id.org/biolink/vocab/provided_by NeuroDKG http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association https://w3id.org/biolink/vocab/publications https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491aea85-5a55-4a7c-b1cf-a123fea4377d http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#cohort http://www.w3.org/2000/01/rdf-schema#label elderly patients http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#cohort https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Cohort http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#cohort https://w3id.org/biolink/vocab/has_phenotype https://identifiers.org/MONDO:0006694 https://identifiers.org/CHEBI:2619 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug https://identifiers.org/MONDO:0001945 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#provenance http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#pubinfo http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#sig http://purl.org/nanopub/x/hasSignature GfcBxtx7MYzp1egS6caWpXsTFJ64EuMLYbTXdUEb946btKnvnz+LkRZn3jQMVg/2cOl9zr2vn0EZ4MLbC5LS2XRa2VGxQq7cQw0/5aMjy8zJoSOP0EkMNtZqZz3ldL8UwKhxM1RKPecT5caofdBbZkw/uo+N2bV0at+VdJgn9Pc= http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://purl.org/dc/terms/created 2021-03-23T20:10:21.164+01:00 http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RA59AEpaWRaR9sjdA0-n4zaQWdiZ6--iGafMrjrDAOheI